nerandomilast
Generic: NERANDOMILAST·Brand: JASCAYD, Jascayd
nerandomilast: 1 clinical trial tracked.
nerandomilast evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about nerandomilast, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)
Primary endpoint: Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] on high-resolution computed tomography (HRCT) at Week 26
InterventionalRandomizedquadruple400 targetStarted 2025-09Completion 2027-0750 sites · Australia, Austria, China, United StatesBoehringer Ingelheim